子宫内膜癌子宫切除术中使用宫内举宫器:肿瘤学结局的系统综述与荟萃分析
该系统综述与荟萃分析纳入2项随机对照试验和12项观察性研究共5019例患者,评估腹腔镜或机器人子宫切除术中使用宫内举宫器对子宫内膜癌肿瘤学结局的影响。举宫器使用与复发风险(HR 1.52,95%CI 0.99-2.33;P=.05)及总生存(HR 1.07,95%CI 0.65-1.76;P=0.79)均无显著关联,腹膜细胞学阳性或淋巴血管间隙浸润率亦无差异,但需进一步前瞻性研究。
要点
- 举宫器使用与复发风险无显著关联(HR 1.52,95%CI 0.99-2.33;P=.05)。
- 举宫器使用与总生存无显著关联(HR 1.07,95%CI 0.65-1.76;P=0.79)。
- 腹膜细胞学阳性或淋巴血管间隙浸润率在举宫器使用与否间无差异。
核心结论
- 子宫内膜癌子宫切除术中使用宫内举宫器与无复发生存和总生存均无显著关联,与腹膜细胞学阳性或淋巴血管间隙浸润亦无显著关联,但需进一步前瞻性研究。
研究设计与样本
- 系统综述与荟萃分析,检索多个电子数据库从建库至2023年1月31日,纳入英文研究比较使用与不使用宫内举宫器的全腹腔镜或机器人子宫切除术的子宫内膜癌患者肿瘤学结局,不限制研究设计。
- 共纳入2项随机对照试验和12项观察性研究,合计14项研究、5019例患者。
- 由4名评审员独立筛选文献、评估偏倚风险并提取数据,采用随机效应模型合并风险比(HR)及95%置信区间,用I²检验量化异质性,通过漏斗图和Egger检验评估发表偏倚。
主要发现
- 举宫器使用与复发的合并HR为1.52(95%CI 0.99-2.33;P=.05;I²=31%;卡方P值=.22)。
- 仅纳入随机对照试验时,举宫器使用与复发的合并HR为1.48(95%CI 0.25-8.76;P=.62;I²=67%;卡方P值=.08)。
- 举宫器使用与总生存的合并HR为1.07(95%CI 0.65-1.76;P=0.79;I²=44%;卡方P值=.17)。
- 使用宫内举宫器与否,腹膜细胞学阳性率或淋巴血管间隙浸润率无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to assess the effects on oncologic outcomes of intrauterine manipulator use during laparoscopic hysterectomy for endometrial cancer. DATA SOURCES: A systematic literature search was performed by an expert librarian in multiple electronic databases from inception to January 31, 2023. STUDY ELIGIBILITY CRITERIA: We included all studies in the English language that compared oncologic outcomes (recurrence-free, cause-specific, or overall survival) between endometrial cancer patients who underwent total laparoscopic or robotic hysterectomy for endometrial cancer with vs without the use of an intrauterine manipulator. Studies comparing only peritoneal cytology status or lymphovascular space invasion were summarized for completeness. No selection criteria were applied to the study design. METHODS: Four reviewers independently reviewed studies for inclusion, assessed their risk of bias, and extracted data. Pooled hazard ratios with 95% confidence intervals were estimated for oncologic outcomes using the random effect model. Heterogeneity was quantified using the I2 tests. Publication bias was assessed by funnel plot and Egger test. RESULTS: Out of 350 identified references, we included 2 randomized controlled trials and 12 observational studies for a total of 14 studies and 5,019 patients. The use of an intrauterine manipulator during hysterectomy for endometrial cancer was associated with a pooled hazard ratio for recurrence of 1.52 (95% confidence interval, 0.99-2.33; P=.05; I2=31%; chi square P value=.22). Pooled hazard ratio for recurrence was 1.48 (95% confidence interval, 0.25-8.76; P=.62; I2=67%; chi square P value=.08) when only randomized controlled trials were considered. Pooled hazard ratio for overall survival was 1.07 (95% confidence interval, 0.65-1.76; P=0.79; I2=44%; chi square P value=.17). The rate of positive peritoneal cytology or lymphovascular space invasion did not differ using an intrauterine manipulator. CONCLUSION: Intrauterine manipulator use during hysterectomy for endometrial cancer was neither significantly associated with recurrence-free and overall survival nor with positive peritoneal cytology or lymphovascular space invasion, but further prospective studies are needed.
引用
- Zorzato PC, Uccella S, Biancotto G, et al. Intrauterine manipulator during hysterectomy for endometrial cancer: a systematic review and meta-analysis of oncologic outcomes. Am J Obstet Gynecol. 2023. PMID: 37704174. doi:10.1016/j.ajog.2023.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。